Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions.
Brunstein
M G
MG
Belmonte-de-Abreu
P
P
Souza
D O
DO
Lara
D R
DR
D000241:Adenosine / Q000378:metabolism; D004176:Dipyridamole / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy*
D010726:Phosphodiesterase Inhibitors; D017448:Receptors, Dopamine D2; D018698:Glutamic Acid; D004176:Dipyridamole; D000241:Adenosine